


PHARMACEUTICAL 2023

LUMOS PHARMA INC. Rank 134 of 446










PHARMACEUTICAL 2023



Rank 134 of 446

The relative strengths and weaknesses of LUMOS PHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LUMOS PHARMA INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points. The greatest weakness of LUMOS PHARMA INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 168%, being 125% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	72,009
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,708
Liabilities, Non-Current	6,000
Other Assets	230
Other Compr. Net Income	-9.0
Other Expenses	-13
Other Liabilities	0
Other Net Income	965
Other Revenues	1,523
Property and Equipment	53
Research and Development	17,857
Selling, General and Administrative Expense	15,706

Output Variable	Value in 1000 USD
Assets	72,292
Liabilities	12,708
Expenses	33,550
Revenues	1,523
Stockholders Equity	59,584
Net Income	-31,062
Comprehensive Net Income	-31,066
Economic Capital Ratio	168%

